Forest Laboratories & Almirall Announce Positive Results for the Second Phase III Study for Aclidinium & Formoterol combinati...
May 01 2013 - 2:17PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC)
today announced positive topline results from AUGMENT COPD, the
second six-month pivotal phase III clinical trial evaluating the
efficacy and safety of investigational fixed dose combinations of
aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered
in the Pressair® (Genuair® outside the USA) inhaler.
The 400/12mcg combination of aclidinium/formoterol demonstrated
statistically significant improvements in change from baseline for
the co-primary endpoints of Forced Expiratory Volume (FEV1) at 1
hour post-dose versus aclidinium 400mcg (P
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024